Additional Supporting Information may be found in the online version of this article.

hep26398-sup-0001-suppfig1.tif5562KSupporting Information Figure 1
hep26398-sup-0002-suppfig2.tif3731KSupporting Information Figure 2
hep26398-sup-0003-suppfig3.tif1200KSupporting Information Figure 3
hep26398-sup-0004-suppfig4.tif1652KSupporting Information Figure 4
hep26398-sup-0005-suppfig5.tif1219KSupporting Information Figure 5
hep26398-sup-0006-supptab1.doc34KTable S1. Clinicopathologic features of patients from two cohorts
hep26398-sup-0007-supptab2.doc35KTable S2. Primary antibodies for western blot, immunohistochemistry and co-immunoprecipitation
hep26398-sup-0008-supptab3.doc80KTable S3. Comparison of clinicopathologic profiles between HCC patients of high PROX1 level and low PROX1 level in cohort 1
hep26398-sup-0009-supptab4.doc39KTable S4. Prognostic values of variables for overall survival, recurrence and early recurrence
hep26398-sup-0010-suppinfo.doc42KSupporting Information

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.